Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn’s Disease and Ulcerative Colitis

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

(2016) Parambir S Dulai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab

(2016) Tim Wyant et al.   Journal of Crohns & Colitis

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Adalimumab Induces Deep Remission in Patients With Crohn's Disease

(2013) Jean–Frédéric Colombel et al.   Clinical Gastroenterology and Hepatology

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mucosal healing in inflammatory bowel diseases: a systematic review

(2012) Markus F Neurath et al.   GUT

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease

(2009) Fabian Schnitzler et al.   INFLAMMATORY BOWEL DISEASES

Is chromoendoscopy the new standard for cancer surveillance in patients with ulcerative colitis?

(2009) Markus F Neurath et al.   Nature Reviews Gastroenterology & Hepatology